Salicylic Acid Acne Patches
Salicylic Acid 0.5%
Yiwu Haoding Medical Co.,ltd
Human Otc Drug
NDC 69139-120Salicylic Acid Acne Patches also known as Salicylic Acid 0.5% is a human otc drug labeled by 'Yiwu Haoding Medical Co.,ltd'. National Drug Code (NDC) number for Salicylic Acid Acne Patches is 69139-120. This drug is available in dosage form of Patch. The names of the active, medicinal ingredients in Salicylic Acid Acne Patches drug includes Salicylic Acid - .5 mg/100mg . The currest status of Salicylic Acid Acne Patches drug is Active.
Drug Information:
| Drug NDC: | 69139-120 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Salicylic Acid Acne Patches |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Salicylic Acid 0.5% |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Yiwu Haoding Medical Co.,ltd |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Patch |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | SALICYLIC ACID - .5 mg/100mg
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 15 Sep, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 04 May, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part333D |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | YIWU HAODING MEDICAL CO.,LTD
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 1994404
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UPC: | 0064323358002
|
| UPC stands for Universal Product Code. |
| UNII: | O414PZ4LPZ
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 69139-120-01 | 48 PATCH in 1 BOX (69139-120-01) / 23.1 mg in 1 PATCH | 15 Sep, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Acne treatment
Product Elements:
Salicylic acid acne patches salicylic acid 0.5% salicylic acid salicylic acid carboxymethylcellulose sodium styrene hydrogenated c6-20 polyolefin (100 cst) mineral oil pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) polyisobutylene (1300 mw) propylene glycol tea tree oil
Indications and Usage:
Use for the treatment of acne
Warnings:
For external use only
Do Not Use:
For external use only
When Using:
Using other topical acne medications at the same time or immediately following use of this product may increase dryness or irritation of skin. if this occurs, only one medication should be used unless directed by a doctor. avoid contact with eyes.
Dosage and Administration:
Directions sensitivity test for new user prior to first use, conduct a 24-hour patch test on a small area of your arm on clean, dry skin to determine skin reactivity. proceed with normal usage only if irritation does not occur, as directed below. cleanse face with soap and warm water to remove all traces of oil and dirt. select a dot-shaped patch that is larger than the acne blemish and adhere the patch over the area to be treated. after 8 hours remove by gently peeling back and discarding. cleanse the treated area and apply another patch if desired.
Stop Use:
Stop use and ask a doctor if irritation or redness develops and persists.
Package Label Principal Display Panel:
Product image
Further Questions:
Question? 1-800-548-4097